Halberd Corporation (HALB)
USD 0.0
(3.23%)
USD 0.0
(3.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -74.27 Thousand USD | 83.35% |
| 2023 | -446.16 Thousand USD | 72.43% |
| 2022 | -1.61 Million USD | -89.1% |
| 2021 | 84.69 Thousand USD | 47.96% |
| 2020 | 7797.00 USD | -7401.32% |
| 2019 | -21.92 Thousand USD | -54.04% |
| 2018 | -14.23 Thousand USD | 91.53% |
| 2017 | -307.05 Thousand USD | -460.33% |
| 2016 | 75.05 Thousand USD | 0.0% |
| 2008 | -35.04 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -10.85 Thousand USD | -30.17% |
| 2024 Q4 | -6885.00 USD | 36.57% |
| 2024 Q2 | -8340.00 USD | 82.55% |
| 2024 Q1 | -47.79 Thousand USD | -82.25% |
| 2023 Q3 | -79.86 Thousand USD | 25.33% |
| 2023 Q4 | -26.22 Thousand USD | 67.17% |
| 2023 Q1 | -233.12 Thousand USD | 9.79% |
| 2023 FY | - USD | 72.43% |
| 2023 Q2 | -106.95 Thousand USD | 54.12% |
| 2022 Q4 | -258.4 Thousand USD | 12.59% |
| 2022 Q3 | -295.63 Thousand USD | 58.55% |
| 2022 Q2 | -713.17 Thousand USD | -171.79% |
| 2022 FY | - USD | -89.1% |
| 2022 Q1 | -262.4 Thousand USD | -34.22% |
| 2021 Q4 | -195.5 Thousand USD | 14.34% |
| 2021 FY | - USD | 47.96% |
| 2021 Q3 | -228.23 Thousand USD | -103.89% |
| 2021 Q2 | 5.86 Million USD | 199.7% |
| 2021 Q1 | -5.88 Million USD | 0.0% |
| 2020 FY | - USD | -7401.32% |
| 2019 FY | - USD | -54.04% |
| 2018 FY | - USD | 91.53% |
| 2017 FY | - USD | -460.33% |
| 2016 FY | - USD | 0.0% |
| 2009 Q3 | -364.79 Thousand USD | -205.73% |
| 2009 Q2 | -119.32 Thousand USD | -998.01% |
| 2009 Q1 | -10.86 Thousand USD | -106.12% |
| 2008 Q3 | -155.17 Thousand USD | -170.03% |
| 2008 Q2 | -57.46 Thousand USD | -359062.5% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | -16.00 USD | 0.0% |
| 2008 Q4 | 177.43 Thousand USD | 214.34% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.895% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 98.747% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.884% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 99.572% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.079% |
| Mesoblast Limited | -62.38 Million USD | 99.881% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 95.164% |
| Genus plc | 73.7 Million USD | 100.101% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 98.877% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 97.906% |
| Marizyme, Inc. | -34.28 Million USD | 99.783% |
| ContraFect Corporation | -64.99 Million USD | 99.886% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 99.153% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 98.359% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 94.701% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 97.191% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 96.804% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 85.662% |
| Accustem Sciences Inc. | -3.74 Million USD | 98.017% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.846% |
| EV Biologics, Inc. | -1.26 Million USD | 94.138% |
| Q BioMed Inc. | -617.62 Thousand USD | 87.974% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 102.079% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 88.255% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 96.749% |
| Biomind Labs Inc. | -1.03 Million USD | 92.82% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 100.752% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 98.963% |
| Skye Bioscience, Inc. | -13.54 Million USD | 99.452% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 95.006% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -197.116% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 98.088% |
| IMV Inc. | -35.52 Million USD | 99.791% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.532% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 97.031% |
| GB Sciences, Inc. | -1.41 Million USD | 94.769% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.235% |
| HST Global, Inc. | -5303.00 USD | -1300.698% |
| CSL Limited | 4.78 Billion USD | 100.002% |
| Enzolytics Inc. | -2.12 Million USD | 96.5% |
| Resverlogix Corp. | -11.74 Million USD | 99.367% |
| Affymax, Inc. | -14.29 Million USD | 99.48% |
| SYBLEU INC | -141.57 Thousand USD | 47.532% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 97.575% |
| argenx SE | -216.02 Million USD | 99.966% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.866% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 106.103% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 95.044% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 119.607% |
| AVAX Technologies, Inc. | -6.11 Million USD | 98.785% |
| Zenith Capital Corp. | -8.6 Million USD | 99.137% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.97% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -326.376% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 96.964% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 57.802% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 99.813% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 97.432% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 92.901% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 1204.685% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 95.755% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 96.133% |
| BioStem Technologies, Inc. | -7.55 Million USD | 99.017% |
| ONE Bio Corp. | 13.61 Million USD | 100.546% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 58.982% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 96.389% |
| Agentix Corp. | -1.37 Million USD | 94.585% |
| LadRx Corporation | 412.28 Thousand USD | 118.017% |
| Cell Source, Inc. | -4.27 Million USD | 98.261% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 79.773% |
| Regen BioPharma, Inc. | 1.46 Million USD | 105.067% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 92.072% |
| NovAccess Global Inc. | -1.03 Million USD | 92.822% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.839% |
| Itoco Inc. | -1.86 Million USD | 96.026% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 80.433% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 93.344% |
| Kadimastem Ltd | -2.62 Million USD | 97.17% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 68.94% |
| CytoDyn Inc. | -18.02 Million USD | 99.588% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 6.01% |
| Mobile Lads Corp. | -2.24 Million USD | 96.686% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -507.4% |
| Qrons Inc. | -40.08 Thousand USD | -85.322% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 84.706% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 114.083% |
| Rebus Holdings, Inc. | -951 Thousand USD | 92.189% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 93.006% |
| International Stem Cell Corporation | 202 Thousand USD | 136.772% |
| Bioxytran, Inc. | -3.82 Million USD | 98.056% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -41.108% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 96.983% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 99.793% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -65.064% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 97.287% |
| Neutra Corp. | -181.24 Thousand USD | 59.018% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 99.632% |
| PureTech Health plc | -11.62 Million USD | 99.361% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 99.632% |
| IXICO plc | -707 Thousand USD | 89.494% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 99.033% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.846% |
| CSL Limited | 4.73 Billion USD | 100.002% |
| Cellectis S.A. | -92.63 Million USD | 99.92% |